Sygnature Discovery, a leading integrated discovery and pre-clinical solutions provider, expanded its drug metabolism and pharmacokinetics (DMPK) capabilities by acquiring XenoGesis, the UK's largest independent laboratory-based contract research organization (CRO) specializing in pre-clinical DMPK, quantitative bioanalysis, in vitro pharmacology, and expert interpretation. This acquisition effectively doubled the size of Sygnature's DMPK department, enhancing its discovery and development expertise and complementing its existing service offerings. Both companies are located at BioCity in Nottingham, fostering a collaborative environment that facilitates seamless drug discovery and innovative solutions for clients.